Beyond capacity: biopharma companies need agile manufacturing partners

Published: 13-Mar-2025
Manufacturing

To succeed in the biopharmaceutical industry, organisations require a future-focused lens. What is in the clinical pipeline? What will demand look like in 5 years? When are key patents expiring and how will that impact competition?

You need to be a subscriber to read this article.
Click here to find out more.

Among other key factors, this forecasting helps to guide manufacturing decisions and ensure that enough internal and external capacity is available worldwide for the timely delivery of critical therapies.

With the rapid growth of the industry, capacity is not guaranteed. According to Fortune Business Insights, the world’s biopharmaceutical sector is projected to grow from $617 billion in 2024 to just less than $1.2 trillion by 2032.1  

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • Samsung Biologics
See more

You may also like

Manufacturing

Samsung Biologics bags $668 manufacturing deal with European pharmaceutical company

Read more
The CDMO will be responsible for the manufacture of the client's biopharmaceuticals until December 2031

Trending Articles

  1. Amgen pours $900m into US manufacturing capacity with Ohio expansion The biopharmaceutical company will expand the Ohio facility's operations and construct a second manufacturing plant in Holly Springs, North Carolina
  2. PCI Pharma Serives acquires US-based sterile fill-finish CDMO, Ajinomoto Althea This acquisition will add antibody-drug conjugate (ADC) manufacturing and US-based sterile fill-finish production capabilities to PCI's portfolio
  3. Thermo Fisher Scientific to invest $2bn into US manufacturing capabilities The life science service provider will put 75% of the $2bn into its US pharmaceutical manufacturing capacities, helping to produce key medicines for the market
  4. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  5. RCPE and InSilicoTrials to digitalise and accelerate the development of pharmaceutical manufacturing processes RCPE and InSilicoTrials have agreed to an exclusive partnership to commercialise the XPS simulation software. Specifically developed for pharmaceutical applications, XPS allows companies to assess their process configurations in unprecedented detail and explore the decision space without time- and labour-intensive experiments

Upcoming event

Boosting Sustainability and Efficiency in Pharma Manufacturing

14 May 2025 | Virtual See all

You may also like

Manufacturing

Samsung Biologics bags $668 manufacturing deal with European pharmaceutical company

The CDMO will be responsible for the manufacture of the client's biopharmaceuticals until December 2031
Manufacturing

Samsung Biologics signs $1.24bn biopharma manufacturing deal with Asian pharmaceutical giant

The CDMO will work with the client until the end of 2037, and will use its South Korean biomanufacturing site to serve them
Manufacturing

Navigating biologics chemistry, manufacturing and controls with an innovative CDMO

Drug development is a journey. From the initial discovery of a druggable target through to commercialisation, biopharma companies face an uphill battle when designing, optimising and advancing safe and efficacious drugs
Manufacturing

Overcoming bio/pharmaceutical production hurdles: an industry insider perspective

From F-gas regulation to finance and from biologics to personalised medicines, the global drug production environment faces a number of challenges that could potentially stifle innovation and profitability. Dr Kevin Robinson (KSR) recently spoke to key players in the supplier and outsourcing community to better understand what services and solutions are available to keep the pipeline flowing
Manufacturing

Samsung enters agreement on manufacture of antibody cancer drug

Building on their existing manufacturing agreement, Bristol Myers Squibb and Samsung Biologics have announced an agreement for large-scale manufacture of a Bristol Myers Squibb commercial antibody cancer drug substance
Manufacturing

Unearthing the potential of CDMO services to accelerate complex biologics development

The biologics landscape continues to transform in response to technological advancements and a growing understanding of molecular biology and biochemistry. As a result, an influx of both novel and complex therapeutics is entering the development pipeline, including bispecific antibodies (BsAbs), fusion proteins and antibody-drug conjugates (ADCs). However, these new moieties bring unique and potentially unfamiliar development and manufacturing difficulties
Manufacturing

Samsung Biologics and Pfizer's collaboration for manufacturing of biosimilars

Under the terms of the new agreement, Samsung Biologics will provide Pfizer with additional capacity for large-scale manufacturing for a multi-product biosimilars portfolio
Subscribe now